Posted on September 26, 2011 by Sitemaster
According to another study presented at the European Multidisciplinary Cancer Congress (EMCC) in Stockholm this weekend, the bone-strengthening bisphosphonate ibandronate (Boniva®) seems to work just as well as radiotherapy for the management of pain associated with prostate cancer that has metastasized to the bones. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Boniva, ibandronate, pain, radiation therapy, skeletal-related event, SRE, zoledronate | Leave a comment »
Posted on September 12, 2011 by Sitemaster
Last Friday a U.S. Food & Drug Administration (FDA) advisory committee recommended (based on a 17 to 6 vote) that the labeling of bisphosphonates needed to be updated to make it clear how long patients should take these drugs to gain the greatest benefit and suffer the least risk. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: bisphosphonate, fracture, osteoporosis, Prevention, skeletal-related event | Leave a comment »
Posted on March 4, 2011 by Sitemaster
Full data from the randomized, double-blind, multi-center, Phase III clinical trial comparing denosumab to zoledronic acid in the prevention of skeletal-related events in men with castration-resistant prostate cancer (CRPC) has now been published in The Lancet. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: denosumab, Prevention, skeletal-related event, SRE, zoledronic acid | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 